The Clinical Research Division in the Department of Dermatology conducts ongoing studies of novel therapeutic agents. Established to explore new drugs, devices and therapies, the Clinical Research Division is dedicated to pioneering innovative breakthroughs in the field of dermatology. Housed within the Department of Dermatology, the Clinical Research Division has ample office space and a fully equipped lab dedicated to tissue acquisition and analysis, laser scanning confocal microscopy, and more.
Considering a grant submission? Complete the Intent to Submit Form. This form is used to identify and allocate resources for grant development. It is the first step in planning for the production of high quality, competitive grant applications. This form is used to identify and allocate resources for grant development.
CITI Training is required for all students and residents who are involved in research studies related to human subjects in the Department of Dermatology. The online modules are required prior to a student or resident being added to a research study since the training date must be provided to the IRB. First-time users will need to create an account. After registration, choose the biomedical research group; all modules must be completed. Please send a copy of your completion certificate to Jane Boyer.
Atopic Dermatitis / Eczema
Treatment Of Chronic Itch in Atopic Dermatitis (Eczema)
Study Title: “Treatment of Chronic Itch in Atopic Dermatitis (Eczema) with Oral Clonidine and Oral Naltrexone”
We are recruiting patients with atopic dermatitis (eczema) to participate in a clinical trial. The purpose of this study is to assess the safety and efficacy of two medicines, clonidine and naltrexone, in the treatment of atopic dermatitis (eczema).
Study Length: The study length is up to 9 weeks and involves 7 appointments at the University of Minnesota. Subjects will be randomly chosen to receive either clonidine or naltrexone and will take the medication for a total of 6 weeks. Participation will include safety monitoring labs, EKG, surveys and non-invasive nerve testing.
- Be 18-70 years of age
- Have a diagnosis of atopic dermatitis (eczema)
- Be willing to stop using anti-inflammatory or neuromodulatory medications leading up to or during the study (including topical or oral steroids, allergy and anti-itch medicines, antidepressants, pain medications, and anti-epileptics)
Compensation: Study participants will receive treatment at no charge and will be compensated for their time and effort with $30.00 per visit.
For additional information or to see if you qualify, please call the Department of Dermatology Clinical Research at 612-624-5721 or email email@example.com.
Testing Of Alternatives For Dark Hair Dyes In Patients With Proven Sensitization To Para-Phenylenediamine
Study Title: Testing Of Alternatives For Dark Hair Dyes In Patients With Proven Sensitization To Para-Phenylenediamine
We are seeking adults with a diagnosed allergy to p-phenylenediamine (PPD) and p-toluenediamine (PTD) to participate in a clinical trial. The purpose of this study is to test alternatives for dark hair dyes using standard skin patch tests. The alternatives being tested in this study will be safe for all hair types including black and textured hair.
Study Length: This study will require three study visits, though one of the visits may occur virtually through Zoom. Participation involves a physical exam, allergy history, photo documentation of test arms, and application of the test compounds through standard patch
tests on the upper arms.
- 18-90 years old
- Diagnosis of PPD and/or PTD allergy (patch tests and eczematous reactions to hair dye)
- NOT pregnant or immunocompromised
Compensation: Research study participants will be compensated up to $75 for their time. This study is being conducted by Dr. Paul Bigliardi at the University of Minnesota, Department of Dermatology.
To learn more about this study and to see if you qualify, please contact Irmina
Testing Of Alternatives For Dark Hair Dyes In Patients With Proven Sensitization To
Wallander, firstname.lastname@example.org or 612-624-5721.
Hair Diseases / Alopecia
Study Title: “Mechanism of Immune Modulation by DPCP in Alopecia Areata."
We are recruiting adult participants for a clinical trial. This research involves topical application of the immunomodulatory DPCP to the scalp, as well as the removal of small (4mm) scalp skin biopsy samples.
The study length is approximately 5 months with forty-two visits to the study site.
In 5 months of the study, study participants would have twice weekly visits for scalp and hair examinations and application of the study drug. Scalp biopsies and blood draws would occur at weeks 2, 5, 18 or when hair regrowth is achieved. There is the possibility of optional scalp biopsies at additional time points.
To participate you should:
• be 18 -75 years of age
• have a diagnosis of patchy alopecia areata with 76-99% hair loss
There is no compensation for participating, but volunteers will receive treatment at no charge.
To learn more about the study and to see if you qualify, please call 612-625-7865 or email email@example.com.
Study Title: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CTP-543 IN ADULT PATIENTS WITH MODERATE TO SEVERE ALOPECIA AREATA
We are conducting a research study on individuals with moderate to severe Alopecia Areata. The purpose of this research study is to learn more about the safety and effectiveness of an investigational drug. This study will compare the investigational drug to a placebo (inactive substance) to see how well the investigational drug works.
- Men and women, adults 18- 65 years of age who are in good health
- Diagnosed with severe or very severe Alopecia Areata and have greater than or equal to 50% scalp hair loss
- Must be willing to stop using other types of medications to treat Alopecia Areata throughout the study
- Attend 10 visits over 28 weeks
- Other requirements, which the study team will review with you
This study is being conducted by Dr. Maria Hordinsky in the University Of Minnesota Department Of Dermatology. For additional information, please visit the study page on ClinicalTrials.gov /NCT03732807
Contact the study coordinator: 612-625-2624 or firstname.lastname@example.org
Frontal Fibrosing Alopecia Questionnaire Study
Study Title: “A Research Study to Evaluate Frontal Fibrosing Alopecia – Clinical Portion”
We are recruiting patients with frontal fibrosing alopecia to participate in a research study to learn more about the condition. The University of Minnesota is just one of several institutions in the United States participating in this study, which is led by Dr. Olsen of Duke University. The information gained from this study will be used to help find clues as to the cause of this scarring hair disease.
There are two parts to this study:
- Part 1: An in-person appointment at the University of Minnesota Department of Dermatology. At this appointment, participants will have non-identifying photographs taken of their scalp and their scalp examined.
- Part 2: Participants will complete a detailed online questionnaire with questions about medical history, hair care practices, and family history of hair loss.
- You must have had a scalp biopsy that confirmed the diagnosis of lichen planopilaris/frontal fibrosing alopecia
There is no compensation for participating in this study.
For additional information, please call the Department of Dermatology Clinical Research at 612-624-5721 or email email@example.com.
Photobiomodulation Devices for the Treatment of Alopecia
Study Title: “A Clinical Comparison of FDA-Cleared Photobiomodulation Devices for the Treatment of Alopecia”
We are recruiting adult participants with male and female pattern hair loss for a clinical trial. The purpose of this research study is to gain more information on the effectiveness of photobiomodulation devices which use low level laser therapy to treat scalp hair loss. We will assign participants to one of six FDA-cleared photobiomodulation devices, which are in the form of combs and helmets. Treatment with the device can last between 90 seconds to thirty minutes. As part of the research study, we will collect data including photos of the scalp and questionnaires filled out by research study participants.
Study Length: The research study length is 5 months and involves appointments at the University of Minnesota three times per week. You will receive 4 months of treatment and a 1 month follow up appointment.
Participant Requirements :
- 21-85 years old with male or female pattern hair loss.
- Be willing to stop all hair-growth promoting medications including topical Minoxidil (Rogaine®), finasteride, and dutasteride.
- Be willing to maintain the same hair color and style throughout the duration of the research study.
Compensation: Research study participants will receive treatment at no charge and will receive parking vouchers.
To learn more about the research study and to see if you qualify, please call the Department of Dermatology Clinical Research at 612-624-5721, or email firstname.lastname@example.org.
Cutaneous T-Cell Lymphoma
Cutaneous T-Cell Lymphomas for Mycosis Fungoides (MF or Sezary Syndrome Forms of Cutaneous T-Cell Lymphomas)
Study Title: A Double Blind, Randomized, Vehicle Controlled, Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion, 0.5%, for the Relief of Pruritus in Patients with the Mycosis Fungoides (MF) or Sézary Syndrome Forms of Cutaneous T-Cell Lymphoma (CTCL).
We are conducting a research study on individuals with the Mycosis Fungoides (MF) or Sézary Syndrome (SS) forms of Cutaneous T-cell Lymphoma (CTCL). The purpose of this research study is to learn more about the safety, tolerability and efficacy of an investigational topical drug called Topical Naloxone Hydrochloride Lotion. This study will compare the investigational drug to a placebo lotion (inactive substance) to see how well the investigational drug works. All participants will receive both the active and inactive lotions during the trial.
- Men and Women ages 21 and older
- Diagnosed with Mycosis Fungoides ( MF) or Sézary Syndrome forms of Cutaneous T-Cell
- Lymphoma (CTCL)
- Must be willing to stop using other types of medications to treat Pruritus (itching)narcotics
- and topical antihistamines for the duration of the study
- Other medications may remain stable throughout the trial
- Other requirements, which the study team will review with you
This Study is being conducted by Dr Kimberly Bohjanen at the University of Minnesota Department of Dermatology. For additional information, please visit the study page at ClinicalTrials.gov or call the study coordinator: 612-624-5721 or email: email@example.com